Erin Mulvey, MD, discusses real-world time to treatment discontinuation data for first-line zanubrutinib compared with other BTK inhibitors in CLL.
Erin Mulvey, MD
Advertisement
Erin Mulvey, MD, an assistant professor of Medicine at Weill Cornell Medical College and an assistant attending physician at NewYork-Presbyterian Hospital.
Articles by Erin Mulvey, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to Olomorasib in KRAS G12C+ Pancreatic Cancer
2
FDA Grants Orphan Drug Designation to Zocilurtatug Pelitecan for Neuroendocrine Carcinomas
3
Sapablursen Represents Potential Avenue for Improved Hepcidin Production in Polycythemia Vera
4
OS Wins, New Approvals, and Practice-Changing Data: Breaking Down the Biggest NSCLC News From ASCO 2026
5